Bliss GVS Pharma announces an acquisition

The provided context does not contain the Detailed Public Statement (DPS) or any disclosure regarding an offer price proposed by Anupam Rasayan for Bliss GVS Pharma. Consequently, a comparison between an offer price and the requested metrics cannot be performed.

Regarding the specific financial and market metrics requested:

• 60-day VWAP: While daily closing prices for Bliss GVS Pharma are available from April 22, 2026, to July 23, 2026, the provided data does not include the daily trading volume required to calculate a volume-weighted average price (VWAP).
• Book Value per Share: As of the quarter ended March 31, 2026, Bliss GVS Pharma reported consolidated total equity of Rs 1,192.9 Crores ^[3] and standalone total equity of Rs 1,155.2 Crores ^[4]. However, the total number of outstanding shares is not disclosed in the provided KPI data, preventing the calculation of the book value per share.

No news, analyst coverage, or regulatory filings regarding a proposed offer were retrieved this turn.

Shareholding Impact and Compliance Analysis

If the open offer is fully subscribed, the maximum potential holding of the new promoter group (Anupam Rasayan India Limited and PAC) will reach 69.30%, leaving a minimum public shareholding of 30.70%.

This transaction does not trigger any immediate compliance requirements regarding Minimum Public Shareholding (MPS). Under SEBI regulations, listed companies must maintain a minimum public shareholding of 25% (limiting promoter group holding to 75%). Because the post-transaction public shareholding remains comfortably above the 25% floor, the acquirer faces no regulatory obligation to dilute its stake.

---

Transaction Shareholding Bridge

The table below outlines the shift in shareholding structure assuming full acceptance of the open offer:

• Notes: † Derived by summing the SPA and Open Offer percentages/shares. ‡ Derived as the residual of the expanded voting share capital.*

---

Key Analytical Implications

• No Regulatory Overhang: Because the combined promoter holding of 69.30% sits below the 75% threshold, Anupam Rasayan is not subject to SEBI's mandatory 12-month dilution window. This eliminates the risk of a near-term market overhang from a forced Offer for Sale (OFS) or institutional placement to restore MPS.
• Absolute Operational Control: Achieving a 69.30% stake gives Anupam Rasayan robust control over Bliss GVS Pharma ^[5]. This level of ownership is well above the 50% threshold required for ordinary resolutions and close to the 75% threshold required for special resolutions, facilitating smooth operational integration and strategic decision-making.
• Cash Outflow Certainty: At the fixed open offer price of Rs 299 per share ^[5], a fully subscribed offer will require a cash outlay of Rs 829.03 Crores ^[5] (reported as approximately Rs 829 Crores ^[7]). This represents a clean cash exit option for public shareholders without altering the listing status of the company.

---

Material Gaps and Caveats

• Existing Promoter Residuals: The SPA involves acquiring shares from "existing promoters and public shareholders" ^[5]. The reported material does not disclose whether any existing promoters will retain a residual stake post-transaction, or if they will be entirely reclassified as public shareholders. If any existing promoters retain shares and are not reclassified, their holdings must be added to the 69.30% figure to determine the final promoter group total. However, there is a comfortable 5.70 percentage point buffer before breaching the 75% MPS ceiling.
• Pre-Transaction Shareholding Split: The exact pre-transaction shareholding pattern of Bliss GVS Pharma is not separately disclosed in the reported material.*